Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2018 Jul;32(7):1598-1608. doi: 10.1038/s41375-018-0034-z. Epub 2018 Feb 23.

2.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.350. [Epub ahead of print]

PMID:
29249818
3.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichmann M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk RF, Döhner K, Döhner H, Ganser A, Heuser M.

Leukemia. 2017 Jun;31(6):1286-1295. doi: 10.1038/leu.2016.345. Epub 2016 Nov 24.

PMID:
27881874
4.

Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.

Bhatnagar B, Eisfeld AK, Nicolet D, Mrózek K, Blachly JS, Orwick S, Lucas DM, Kohlschmidt J, Blum W, Kolitz JE, Stone RM, Bloomfield CD, Byrd JC.

Br J Haematol. 2016 Oct;175(2):226-236. doi: 10.1111/bjh.14254. Epub 2016 Aug 1.

5.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

6.

High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.

Candoni A, De Marchi F, Zannier ME, Lazzarotto D, Filì C, Dubbini MV, Rabassi N, Toffoletti E, Lau BW, Fanin R.

Leuk Res. 2017 Dec;63:22-27. doi: 10.1016/j.leukres.2017.10.010. Epub 2017 Oct 27.

PMID:
29096332
7.

Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.

Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J, Beinicke S, Häntschel J, Cross M, Vucinic V, Pönisch W, Behre G, Franke GN, Lange T, Niederwieser D, Schwind S.

Ann Hematol. 2018 Oct;97(10):1757-1765. doi: 10.1007/s00277-018-3373-y. Epub 2018 May 22.

PMID:
29785446
8.

Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.

Stölzel F, Hackmann K, Kuithan F, Mohr B, Füssel M, Oelschlägel U, Thiede C, Röllig C, Platzbecker U, Schetelig J, Illmer T, Schaich M, Seliger B, Hartmann A, Baretton G, Zietz C, Ehninger G, Schrock E, Bornhäuser M.

Transplantation. 2012 Apr 15;93(7):744-9. doi: 10.1097/TP.0b013e3182481113.

PMID:
22314337
9.

FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study

Ardestani MT, Kazemi A, Chahardouli B, Mohammadi S, Nikbakht M, Rostami S, Jalili M, Vaezi M, Alimoghaddam K, Ghavamzadeh A.

Turk J Haematol. 2018 Aug 3;35(3):158-167. doi: 10.4274/tjh.2018.0017. Epub 2018 May 22.

10.

Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.

Luskin MR, Carroll M, Lieberman D, Morrissette JJD, Zhao J, Crisalli L, Roth DB, Luger SM, Porter DL, Reshef R.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1961-1967. doi: 10.1016/j.bbmt.2016.07.018. Epub 2016 Jul 28.

11.

Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.

Sun Y, Shen H, Xu T, Yang Z, Qiu H, Sun A, Chen S, Wu D, Xu Y.

Leuk Res. 2016 Oct;49:102-7. doi: 10.1016/j.leukres.2016.09.001. Epub 2016 Sep 3.

PMID:
27626217
12.

Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.

Sato S, Itonaga H, Taguchi M, Sawayama Y, Imanishi D, Tsushima H, Hata T, Moriuchi Y, Mishima H, Kinoshita A, Yoshiura KI, Miyazaki Y.

Int J Hematol. 2018 Aug;108(2):213-217. doi: 10.1007/s12185-018-2419-1. Epub 2018 Feb 7.

PMID:
29417354
13.

The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.

Zhao XS, Qin YZ, Liu YR, Chang YJ, Xu LP, Zhang XH, Huang XJ.

Leuk Lymphoma. 2017 May;58(5):1135-1143. doi: 10.1080/10428194.2016.1239264. Epub 2016 Oct 12.

PMID:
27733089
14.

Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.

Candoni A, De Marchi F, Zanini F, Zannier ME, Simeone E, Toffoletti E, Chiarvesio A, Cerno M, Filì C, Patriarca F, Fanin R.

Exp Hematol. 2017 May;49:25-33. doi: 10.1016/j.exphem.2017.01.005. Epub 2017 Feb 1.

PMID:
28159598
15.

Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.

Martín I, Navarro B, Villamón E, Solano C, Serrano A, Calabuig M, Amat P, Domingo F, Abellán R, García F, Olivares MD, Chaves FJ, Tormo M, Hernández-Boluda JC.

Exp Mol Pathol. 2018 Aug;105(1):139-143. doi: 10.1016/j.yexmp.2018.07.002. Epub 2018 Jul 11.

PMID:
30017658
16.

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.

Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F.

J Clin Oncol. 2011 Jun 20;29(18):2507-13. doi: 10.1200/JCO.2010.34.2873. Epub 2011 May 9.

17.

Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may be a prognostic factor for acute myeloblastic leukemia in adults.

Fujisawa S, Maruta A, Motomura S, Fukawa H, Kanamori H, Ogawa K, Matsuzaki M, Miyashita H, Harano H, Murata T, Sakai R, Mohri H, Kodama F, Okubo T.

Leuk Lymphoma. 1998 Mar;29(1-2):161-70.

PMID:
9638985
18.

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.

Berenstein R, Blau IW, Suckert N, Baldus C, Pezzutto A, Dörken B, Blau O.

J Exp Clin Cancer Res. 2015 May 22;34:55. doi: 10.1186/s13046-015-0173-2.

19.

Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.

Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, Birnbaum D, Mozziconacci MJ.

Am J Hematol. 2012 Jul;87(7):659-62. doi: 10.1002/ajh.23211. Epub 2012 Apr 25.

20.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2011 Apr 1;29(10):1373-81. doi: 10.1200/JCO.2010.32.7742. Epub 2011 Feb 22.

Supplemental Content

Support Center